CURRICULUM VITAE
Myung-Ju Ahn, M.D., Ph.D.
Primary Academic Appointments at Sungkyunkwan University Professor, Division of Hemato-Oncology, Department of Medicine
Mailing Address: Division of Hematology-Oncology Department of Medicine Samsung Medical Center, Sungkyunkwan University School of Medicine 50, Il-won dong, Kangnam-gu Seoul, 135-710, KOREA Tel) 82-2- 3410-3438 Fax) 82-2- 3410-1754 Email) [email protected] or [email protected]
Personal: Date of Birth : Jan 24, 1961 Citizenship: KOREA
Education: 1979-1981 Premedicine College of Natural Science Hanyang University Seoul, KOREA 1981-1985 M.D. College of Medicine Hanyang University Seoul, KOREA 1986-1988 Master of Science Thesis: “Chromosomal study in Adult Acute Lymphocytic Leukemia” Graduate School Hanyang University Seoul, KOREA 1988-1991 Ph. D. Thesis: “ B and T cell Abnormalities in Patients with Glomerulonephritis” Graduate School Hanyang University Seoul, KOREA
Professional Training and Academic Career: 1985.3-1986.2 Internship in Medicine Hanyang University Hospital Seoul, KOREA 1986.3-1989.2 Residency in Internal Medicine Hanyang University Hospital Seoul, KOREA 1991.3-1993.2 Clinical fellowship in Hematology-Oncology Asan Medical Center Univesity of Ulsan Seoul, KOREA 1993.3-1995.2 Postdoctoral research fellowship Memorial Sloan-Kettering Cancer Center New York, U.S.A. 1995.3-1999.2 Assistant Professor Division of Hematology-Oncology Department of Medicine Hanyang University KURI Hospital Kyunggi-do, KOREA 2000.3- 2004.2 Associate Professor Division of Hematology-Oncology Department of Medicine Hanyang University Hospital Seoul, KOREA 2005.3- 2006.1 Professor Division of Hematology-Oncology Department of Medicine Hanyang University Hospital Seoul, KOREA 2006.2- present Professor Division of Hematology-oncology Department of Medicine Samsung Medical Center Sungkyunkwan University School of Medicine Seoul, Korea
Certification: 1989 Diplomate, Korean Board of Internal Medicine
License: 1985 Korean Medical License (No : 29406) 1988 Board of Korean Internal Medicine (No: 2655) 1997 Subspecialty Board of Hematology-Oncology (No: 97-123)
Honors: 1979-1985 CUM LAUDE, Scholarship College of Medicine Hanyang University , Seoul, Korea
1994 Outstanding Poster in 86th AACR meeting Toronto, CANADA 2003 Best researcher Awards from Korean Medical Women’s Association
Affiliations: Member, Korean Medical Association Member, Korean Association of Internal Medicine Member, Korean Association of Cancer Member, Korean Association of Clinical Oncology Member, Korean Association of Hematology Member, Korean Association of stem cell transplantation Member, American Association for Cancer Research Member, American Society of Oncology Member, International Society of Lung Cancer Association Member, European Society of Medical Oncology Member, Korean Cancer Study Group Professional Recognition 2012–present Chief, Executive Committee of Korean Cancer Study Group 2006-2011 Chief, Educational Committee of Korean Cancer Study Group 2008-present, Board Member, Korean Association of Cancer 2008-present, Board Member, Korean Association of Clinical Oncology
2011-present, Member, Educational Committee of IASLC 2013-present, Editorial Board Member, Journal of Thoracic Oncology
Training on ICH/GCP I received GCP training at investigator meetings related with clinical trials listed above. I have also received GCP training through IRB.
Original article
1. Kyoo Hyung Lee, Jung Shin Lee, Cheolwon Suh, Myung Ju Ahn, Sang We Kim, Byung Soon Doh, Young Il Min, Byung Sik Kim, Kun Choon Park, In Cheol Lee, Young Joo Cho, Mi Gyung Choi, Sang-Hee Kim. DNA Flow Cytometry of Stomach Cancer. Cancer 1993;72:1819-1826
2. Kyoo Hyung Lee, Jung Shin Lee, Cheolwon Suh, Myung Ju Ahn, Sang We Kim, Byung Soon Doh, Young Il Min, Byung Sik Kim, Kun Choon Park, In Cheol Lee, Young Joo Cho, Mi Gyung Choi, Sang-Hee Kim. A complete remission can be achieved despite persistence of abnormal bone marrow promyelocytes in acute promyelocytic leukemia- experience in 2 patients. J Korean Med Sci 1993:8:246-50.
3. Myung Ju Ahn, Jung Shin Lee, Kyoo Hyung Lee, Cheolwon Suh, Sun Sook Choi, Sang-Hee B. Kim. A Randomized Double-Blind Trial of Ondansetron Alone Versus in Combination with Dexamethasone Versus in Combination with Dexamethasone and Lorazepam in the Prevention of Emesis Due to Cisplatin-Based Chemotherapy. Am J Clin Oncol 1994;17:150-156
4. Myung-Ju Ahn, Kathryn Nason-Burchenal, Mark M Moasser and Ehtan Dmitrovsky. Growth suppression of acute promyelocytic leukemia cells having increased expression of the non-rearranged alleles: RAR or PML. Oncogene 1995;10:2307-2314
5. Myung-Ju AHN, Yun-Hee NOH and Yong-Sung LEE. Telomease Activity in Head and Neck Cancer The Korean Jorunal of Biochemistry 1995;27:219-223
6. Myung-Ju Ahn, John Langenfeld, Mark M Moasser, Vlerie Rusch, Ethan Dmitrovsky. Growth suppression of transformed human bronchial epithelial cells by all-trans retinoic acid occurs through specific reitnoid receptors. Oncogene 1995:11:2357-2364.
7. John Langenfeld, Fulvio Lonardo, Hiroaki Kiyokawa, Tina Passalaris, Myung-Ju Ahn Valerie Rusch, Ethan Dmitrovsky. Inhibited transformation of immortalized human bronchial epithelial cells by retinoic acid is linked to cyclin E down-regulation. Oncogene 1996;13:1983-1990
8. M.-J. Ahn, Y.H. Noh, Y.S. Lee, J.H. Lee, T.J. Chung, I.S. Kim, I.Y. Choi, S.H. Kim, J.S. Lee and K.H. Lee. Telomerase activity in gastric cancer and its clinicopathologic significance. European Journal of Cancer. 1997;33:1309-1313
9. Jong Soo Choi, Kyoo Hyung Lee, Myung Ju Ahn, Jung shin Lee, Je Han Lee, Dae Young Zang, Chel Won Suh, Sang We Kim, Woo Gun Kim, Jin Cheon Kim, Suk koo Kim, Kun Choon Park, Moo Song Lee, Sang-Hee Kim. A Randomized Trial Comparing Cisplatin Plus 5-fluorouracil With or Without Levamisole in Operable Gastric Cancer. The Korean Jorunal of Internal Medicine : 1997;12:155-162
10. Myung-Ju Ahn, Kyung Tae, Yong-Soo park, In-Soon Kim, II-Young Choi, Hyung-Seok Lee, Sun- Kon Kim and Yong-Sung Lee . Telomerase activity in benign and malignant human thyroid nodules Korean Society of Medical Biochemistry and Molecular Biology
11. In Soon Kim, Chan Kum Park, Hawk Kim, Young Yul Lee, Myung Ju Ahn,Woong Soo Lee. Epstein Barr Virus Associated Hemophagocytic Syndrome -A Case Report. Jorunal of Korean Medical Science 1997;12:447-451
12. Myung-Ju Ahn, Suck-Jung Oh, Young-Youl Lee, Tae-Jung, In-Soon Kim, II-Yong Choi, Se-Jin Jang, Yong-Wook Park, Ki-Yong Shin, Yong-Soo Kim A Case of Prostate Cancer in 34 year old man Presenting with Generalized Lymphadenopathy mimicking Malignant Lymphoma. Journal of Korean Medical Science 1997;12:262-265
13. Myung-Ju Ahn, Byoung-Hun Kim, Se-Jin Jang, Eun-Kyung Hong, Won-Mi Lee, Hong-Kyu Baik, Hwon-Kyum Park, Chul Burm Lee, Moran Ki. Expression of Cyclin D1 and Cyclin E in Human Gastric Carcinoma and its Clinicopathologic Significance. Jorunal of Korean Medical Science 1998;13:513-518
14. Se Jin Jang, Myung Ju Ahn, Seung Sam Paik, Gu Kong,. Joo Seob Keum, Yong Wook Park, Jung Dal Lee. Expression of Cyclin Dependent Kinase Inhibitor p21WAF1 alone and in Combination With p27KIP1 shows Prognostic Value in Gastric Carinoma. Journal of Korean Medical Science 1998;13:369- 376
15. Seok Chol Jeon, Heung Suk Seo, Chang Kok Hahm, Myung Ju Ahn. Treatment of Invasive Pulmonary Aspergillosis by Combined Intravenous and Transthoracic Injection of Amphotericin B in a Patients with Acute Leukemia: A Case Report J Korean Radiol Soc 1998;39:705-708
16. Myung-Ju Ahn, Dong-Su Han, Joo Hyun Sohn, Yong-Cheol Jeon, Dae-Won Jun, Nak-Won Choi,, Hwon-Kyum Park, Hong-Kyu Baik, Hong-Gi Lee, Young-Soo Nam, II-Young Choi. Combination Chemotherapy of oral 5’-deoxy-5-fluorouridine and Cisplatin in Advanced Gastric Cancer: A Phase II Study. Jorunal of Korean Medical Science 1998;13:612-616
17. Hee-Joon Yu, Yun-Suck Kim, Hong-Yoon Yang, Sang-Jin Kwon, Myung-Ju Ahn, Chan-Kum Park. A Case of Leukemia Cutis. Journal of Korean Medical Science 1998;13:686-692
18. Myung-Ju Ahn, Il-Young Choi, In-Soon Kim. A Case of Successful Engraftment with Uncontrolled Rate Cryopreserved Stem Cells at -80. 대한조혈모세포이식학회지 1999;4:91-95
19. Myung-Ju Ahn, Yun-Hee Noh, Wo-Chul Kim, Hyun-Soo Kim, Young-Yul Lee, Tae-June Jung, Il-Young Choi, In-Soon Kim, Young-Sung Lee. Detection of Tumor Cell Contamination in Peripheral Blood Stem Cells by RT-PCR in High risk or Metastatic Breast Cancer Patients and its Clincal Implications. 대한조혈모세포이식학회지 1999;4:1-11
20. S.-J. Jang, Y,-W. Park, M.-H. Park, J.-D. Lee, Y.-Y. Lee, T.-J. Jung, I.-S Kim, I.-Y. Choi, M.Ki, B.-Y. Choi and M.-J. Ahn. Expression of Cell-cycle regulators, cyclin E and p21WAF1/CIPI, potential prognostic markers for gastric cancer. European Journal of Surgical Oncology 1999;25:157-163
21. YunHee Noh, Griwou Im, Ja-Hyun ku, Yong-Sung Lee, Myung-Ju Ahn. Detection of tumor cell contamination in peripheral blood by RT-PCR in gastrointestinal tract cancer patients. J Korean Med Sci 1999:14:623-628
22. Myung-Ju Ahn, Hawk Kim, In Soon Kim, Jin Kyung Park, Moran Ki, Chan Kem Park. P53 protein expression and its prognositc importance in patients with nodal non-Hodgkin’s lymphoma. J Korean Med Sci 2000:15: 59-64
23. Myung-Ju Ahn, In-hong Lee, Ja-HunJung, Jung-Hye Choi, Kyung-Ran Cho, Seoung-Yun Kim. A case of immunoablative high-dose cyclophosphamide therapy without stem cell rescue in the treatment of refractory rheumatoic arthritis patient. 대한조혈모세포학회지 2000;5:129-133.
24. Hawk Kim, Mi-Ok Kim, Myung-Ju Ahn, Young-Yeul Lee, Tae-June Jung, Il-Young Choi, In- Soon Kim, Chan-Kum Park. Eosinophilic fascitis preceding relapse of peripheral T-cell lymphoma. Journal of Korean Medical Science. 2000:15:346-350.
25. Myung-ju Ahn, Yong-Wook Park, Dong-soo Han, Jung-Hae Choi, Sung-Jun Shin, Byung-Chul Yoon, In-Soon Kim. A case of primary intestinal T-cell lymphoma involving entire gastrointestinal tract: esophagus to rectum. Korean Journal of Internal Medicine. 2000; 15: 245-249.
26. Myung-Ju Ahn, Yun-Hee Noh, Ho-Ju Yoon, Chan-Kum Park. Detection of malignant cells in pleural fluid or ascites by CD44v8-10/CD44v10 competitive RT-PCR. Korean Journal of Internal Medicine. 2001;16:30-36.
27. Yun-Hee Noh, Jung-Ah Kim, G-Rewo Lim, Yong-Sung Lee, Myung-Ju Ahn. Detection of circulating tumor cells in patients with gastrointestinal tract cancer using RT-PCR and its clinical implications. Experimental and Molecular Medicine. 2001;33:8-14.
28. Myung-Ju Ahn, Yun-Hee Noh, Yong-Sung Lee,, Il-Young Choi, In-Soon Kim, Eun-Kyung Joh, Dong-Bock Shin, Si-Young Kim, Kyung-Sam Cho, Hyo-Cheul Kim, Kyun-Soo Kim, Cheolwon Suh, Sang-Hee Kim, Jung-Ae Lee, Young-Suck Park. Clinical impacts of tumor cell contamination of hematopoietic stem cell products in metastatic breast cancer patients undergoing autologous peripheral stem cell transplantation; multicenter trial. Journal of Korean Medical Science. 2001;16:175-182.
29. Hang-Lak Lee, Myung-Ju Ahn, Jung-Hye Choi, Woon Hyun Lun, Young-Ueul Lee, In-Soon Kim, Il Young Choi, Se-Jin Jang, Young-Wook Park. A case of NK/T-cell lymphoma complicated by a squamous cell carcinoma of hard palate during combination chemotherapy and radiation therapy. Korean Journal of Internal Medicine. 2001;16:255-258.
30. Myung-Ju Ahn, Chan-Kum Park, Jung-Hye Choi,. Won-Mee Lee, Moran Ki. Clinical significance of microvessel density in multiple myeloma patients. Journal of Korean Medical Science. 2001;16:45- 50.
31. Jung-Hye Choi, Myung-Ju Ahn, Joon-Sung Park, In-Soon Kim, Woong-Soo Lee. A case of successful engraftement of high-dose melphalan and peripheral blood stem cell transplantation in multiple myeloma with renal insufficiency. 한양의대학술지 2001;21:127-130.
32. Jung-Hye Choi, Myung-Ju Ahn, Mo-ran Ki, Ho-Suk Oh, Young-Yeul Lee, In-Soon Kim. Clinical prognostic factors and treatment outcome of aggressive non-Hodgkin’s lymphoma in elderly patients. 대한암학회지 2001;33:324-328.
33. Myung-Ju Ahn, Yong-Wook Park, Jung-Hye Choi, Ho-Suk Oh, Chul-Bum Lee, Hong-Kyu Paik, Chan-Kum Park. Clinical prognostic values of vascular endothelial growth factor, microvessel density, and p53 expression in esophageal carcinomas. Journal of Korean Medical Science. 2002:17:201-207.
34.Myung-Ju Ahn, Tae-June Jung, Jung-Hye Choi, Mi-Ran Oh, Hwi-Joong Yoon, Jun-Suk Kim, Chul-Won Choi, Kyung-Wook Hur, Dae-Sik Hong, Hee-Sook Park, Sung-Kyu Pare, Jung-Ae Lee, Young-Suk Park, Honggi Jung. Randomized controlled open labelled, phase III trials, comparing the efficacy between Fentas and Durogesic patches in controlling cancer pain: multicenter trial. Cancer Research and Treatment 2002:34:165-169.
35. Ho-Suk Oh, Myung-Ju Ahn, Jung-Hye Choi, Yong-Wook Pare, Byung-Joo Song, Young-Yeul Lee, In-Soon Kim, Il-Young Choi, Jun-Goo Kang, Sung-Joon Shin. A case of bilateral primary orbital MALT lymphoma. Hanyang Journal of Medicine. 2002:22:119-123.
36. Ki-Hwan Lee, Mi-Yoon Chang, Joon-Ik Ahn, Dong-Hyun Yu, Sung-Soo Jung, Jung-Hye Choi, Yun-Hee Noh, Yong-Sung Lee, Myung-Ju Ahn. Differential gene expression in retinoic acid induced differentiation of acute promyelocytic leukemia cells, NB4 and HL-60 cells. Biochemical and Biophysical Research Communications 2002:296:1125-1133.
37. Ki Chan Kim, In Hong Lee, Jung Hye Choi, Mee Ran Oh, Myung-Ju Ahn, Seong Yoon Kim. Autologous stem cell transplantation in the treatment of refractory rheumatoid arthritis. Journal of Korean Medical Science. 2002 17:129-132.
38. Myung-Ju Ahn, Jung-Hae Choi, Sung-Gon Shim, Kyoung-Sun Na, Think-You Kim, Sang- Cheol Bae. Autologous peripheral blood stem cell transplantation in rapidly progressive systemic sclerosis: case report. Korean Journal of Hematopoietic Stem Cell Transplantation. 2002 7(2) :161-166.
39. Oh HS, Choi JH, Park CK, Jung CW, Lee SI, Park Q, Suh C, Kim SB, Chi HS, Lee JH, Bang SM, Ahn MJ. Comparison of microvessel density before and after peripheral blood stem cell transplantation in multiple myeloma patients and its clinical implications: multicenter trial. International Journal of Hematology. 2002:76:465-470 (ISSN No:0925-5710 IF:1.335)
40. Choi JH, Ahn MJ, Jang SJ, Park CK, Park YW, Oh HS, Lee YY, Choi IY, Kim IS. Absence of clinical prognostic value of vascular endothelial growth factor and microvessel denstiy in multiple myeloma. International Journal of Hematology 2002:76:460-464 (ISSN No:0925-5710 IF:1.335)
41. Lee, Hye-Sook, Mi-Yune Jang, Jung-Hye Choi, Young-Yeul Lee, Hyung-Bae Park, Yong-Sung Lee, Seung-Wrong Kim, Myung-Ju Ahn. Comparison of cell proliferation, apoptosis, and telomerase activity in human cord blood CD34+ cells cultured with various cytokine combinations. J Microbiol Biotechol 2003;13(3):422-428.
42. Myung-Ju Ahn, Jung-Hye Choi, Young-Yeul Lee, Il-Young Choi, In-Soon Kim, Sung-Soo Yoon, Sun-Yang Park, Byung-Kook Kim, Cheolwon Suh, Hee Jeong Son, Cheol-Won Jung, Jae Hoon Lee, Ju-Myung Sung, Suck-Ah Im, Doyeun Oh, So-Young Jung, Hwi-Joong Yoon, Kyung-Sam Cho, Jung-Ae Lee, Young-Jin Yuh, Sung-Rok Kim, Moran Ki. Outcome of Adult Severe or Very Severe Aplastic Anemia Treated With Immunosuppressive Therapy Compared to Bone Marrow Transplantation: Multicenter Trial. International Journal of Hematology 2003;78:133-138.
43. Jung-Hye Choi, Myung-Ju Ahn, Seock-Ah Im, Bong-Seog Kim, Ho-Suk Oh, Heung Woo Lee, Yeung Chul Mun, Chu-Myung Seong, Soon Nam Lee, Young-Yeul Lee, Il-Young Choi, In-Soon Kim. Gemcitabine and infusional 5-fluororuacil in advanced pancreatic cancer: A clinical benefit response-oriented phase II study. Cancer Research and Treatment 2003;35(3) 213-217.
44. Soo-Mee Bang, Eun Kyung Cho, Cheolwon Suh, Sung-Soo Yoon, Chu Myung Seong, Kyung Sam Cho, Yoon Goo Kang, Seonyang Park, Myung-Ju Ahn, Young Suk Park, Hugh C. Kim, Chul Won Jung, Samuong Kim, Jae Hoon Lee. High dose therapy followed by autologous peripheral blood stem cell transplantation as a first line treatment for multiple myeloma: a Korean Multicenter Study. Journal of Korean Medical Science 2003;18(5):673-678.
45. Myung-Ju Ahn, Ho-Scuk Oh, Jung-Hye Choi, Young-Yeul Lee, In-Soon Kim, Il-Young Choi, Oh Young Lee, Heung-Woo Lee. Combination chemotherapy of oxaliplatin and capecitabine in patients with metastatic colorectal cancer: a pilot study. Cancer Resarch and Treatment 2003: 35(5),407-410.
46. Hee Young Cho, Mi Kyung Kim, Young Do Yoo, Myung Ju Ahn, Joung Soon.Jang. Proteomic profiling of human small cell lung cancer cell line NCI-H211. Cancer Research and Treatment 2003:35(6), 489-496.
47. Myung-Ju Ahn, Ki-Hwan Lee, Joon-Ik Ahn, Dong-Hyun Yu, Hye-Sook Lee, Jung-Hye Choi, Houng Soon Jang, Jong Min Bae, Yong-Sung Lee. The differential gene expression profiles between sensitive and resistant breast cancer cells to adriamycin by cDNA microarray. Cancer Research and Treatment. 2004:36(1), 43-49.
48. Jung-Hye Choi, Myung-Ju Ahn, Hyunchul Rhim, Heung Woo Lee, Ho-Suk Oh, Young-Yeul Lee, Il-Young, Choi, In-Soon Kim. Radiofrequency ablation for metastatic hepatic tumor in colorectal carcinoma. Cancer Research and Treatment 2004:36(2) 128-131.
49. Hyun-Seok Cho, In-Soon Kim, Hwan Cheol Park, Myung-Ju Ahn, Young-Yil Lee, Chan Kum Park. A case of severe chronic active Epstein-Barr Virus infection with T-cell lymphoproliferative disorder. The Koran Journal of Internal Medicine 2004, 19(2), 124-127.
50. JM Kim, YK Oh, YJ Kim, J Youn, MJ Ahn. Escherichia coli up-regulates proinflammatory cytokine expression in granulocyte/macrophage lineages of CD34+ stem cells via p50 homodimeric NF-Kb. Clin Exp Immunol 2004:137:341-350.
51. Myung-Ju Ahn , Ho-Suk Oh , Jung-Hye Choi, Young-Yeul Lee, Il-Young, Choi, In-Soon Kim, Oh Young Lee, Ho-Soon Choi, Sung-Joon Kwon. Combination chemotherapy of heptaplatin, paclitaxel, and 5-fluorouracil in patients with advanced gastric cancer: a pilot study. Cancer Research and Treatment. 2004, 36(3), 182-186. 52. Young-Woong Won, Young-Hyo Lim, Ho-Yong Park, Ho-Suk Oh, Jung-Hye Choi, Young-Yeul Lee, In-Soon Kim, Il-Young Choi, Myung-Ju Ahn. Phase II study of irinotecan, 5-fluorouracil, and leucovorin in relapsed or metastatic colorectal cancer as first-line therapy. Cancer Research and Treatment 2004, 36(4), 235-239.
53. Jin-Hyun Woo, Sung-Hyun Park, Yoon-Kyung Park, Chan-Bum Choi, Yun-Young Choi, Myung-Ju Ahn, In-Soon Kim. Postsplenectomy recurrence of thrombocytopenia with an accessory spleen. The Korean Journal of Internal Medicine. 2004, 19(3), 199-201.
54. Myung-Ju Ahn, Young-Do Yoo, Ki-Hwan Lee, Joon-Ik Ahn, Dong-Hyun Yu, Hye-Sook Lee, Ho-Suck Oh, Jung-Hye Choi, Yong-Sung Lee. cDNA microarray analysis of differential gene expression in gastric cancer cells sensitive and resistance to 5-fluorouracil and cisplatin. Cancer Research and Treatment 2005 37(1) 54-62.
55. Young-Hyo Lim, Su-Kyoung Park, Ho-Suk Oh, Jung-Hye Choi, Myung-Ju Ahn, Young-Yul Lee, In-Soon Kim. A case of primary plasmacytoma of lymph nodes. The Korean Journal of Internal Medicine 2005, 20(2), 183-186.
56. Byung-Ryul Choi, Myung-Ju Ahn, Woong-Soo Lee, Tae-Hwan Kim, Sang-Cheol Bae, Jae-Bum Jun. Actue erythroleukemia in a rheumatoid arthritis patient during low-dose methotrexate therapy. Rheumatol Int 2005, 25, 311-313.
57. Young-Woong Won, Won Moon, Yeong-Seop Yun, Ho-Suk Oh, Jung-Hye Choi, Young-Yeul Lee, In-Soon Kim, Il-Young Choi, Myung-Ju Ahn. Clinical aspects of pregnancy and delivery in patients with chronic idiopathic thrombocytopenic purpura (ITP). The Korean Journal of Internal Medicine. 2005,20(2) 129-134.
58. Junh-Hye Choi, Myunh-Ju Ahn, Yong-Wook Park, Ho-Suk Oh, Young-Yeul Lee, In-Soon Kim. A case of erythema nodosum and serositis associated with myelodysplastic syndrome. The Korean Journal of Internal Medicine 2005, 20(2), 177-179.
59. Myung-Ju Ahn, Jung-Hye Choi, Ho-Suk Oh, Young-Yeul Lee, In-Soon Kim, Il-Young CHoi, Kang-Hong Lee, Kang-Won Song, Chan-Kum Park. Thymidylate synthase, thymidine phosphorylase, VEGF, and p53 protein expression in primary colorectal cancer for predicting response to 5-fluororuacil-based chemotherapy. Cancer Research and Treatment. 2005, 37(4), 216-222.
60. Ji-Young Moon, Byung-Su Kim, Hye-Ryeon Yun, Jug-Hye Choi, Yong-Yeul Lee, In-Soon Kim, Myung-Ju Ahn. A case of avascular necrosis of the femoral head as initial presentation of chronic myelogenous leukemia. The Korean Journal of Internal Medicine 2005, 20(3), 255-259.
61. Jung Mogg Kim, Nam In Kim, Yu-Kyoung Oh, Young-Jeon Kim, Jeehee Youn, Myung-Ju Ahn. CpG oligodeoxynucleotides induce IL-8 expression in CD34+ cells via mitogen-activated protein kinase-dependent and NF-kB-independent pathways. International Inumology 2005, 17(12), 1525-1531.
62. Jung-Hye Choi, Myung-Ju Ahn, Hyan-Chul Rhim, Jin-Woon Kim, Gang-Hong Lee, Young- Yeul Lee, In-Soon Kim. Comparison of WHO and RECIST criteria for response in metastatic colorectal carcinoma. Cancer. Cancer Res Treat.2005 37(5), 290-293.
63. Nam Su Lee, Hee Sook Park, Jong Ho Won, Dae Sik Hong, Su Taek Uh, Sang Jae Lee, Joo Hang Kim, Se Kyu Kim, Myung Ju Ahn, Jung Hye Choi, Suk Chul Yang, Jung Ae Lee, Keun Seok Lee, Chang Yeol Yim, Yong Chul Lee, Chul Soo Kim, Moon Hee Lee, Kab Do Jung, Hanlim Moon, Yl Sub Lee. Randomized, Multi-center Phase II Trial of Docetaxel Plus Cisplatin Versus Etoposide Plus Cisplatin as the First-line Therapy for Patients with Advanced Non-Small Cell Lung Cancer. Cancer Res Treat. 2005 ; 037 : 332~338.
64. Jung-Hye Choi, Myung-Ju Ahn, Chan-Kum Park, Hong-xiu Han, Sung-Joon Kwon, Youg-Yuel Lee, In-Soon Kim. Phospho-stat3 expression and correlation with VEGF, p53, and b cl –2 in gastric carcinoma using tissue microarray. APMIS 114:, 619-625, 2006
65. Nam Keun Kim, So Young Chong, Moon Ju Jang, Seoung Ho Hong, Heung Sik Kim, Eun Kyung Cho, Jung Ae Lee, Myung Ju Ahn, Chul Soo Kim, Do Yeun Oh. Association of the methyenetetrahydrofolate reductase polymorphism in Korean patients with childhood acute lymphoblastic leukemia. Anticancer Research 26: 2879-2882, 2006
66. YS Hong, HR Lee, S Park, IG Hwang, B-B Park, J Lee, JS Ahn, M-J Ahn, HY Lim, K Park. Three-week schedule of irinotecan plus cisplatin in patients with previously untreated extensive small cell lung cancer. Br J Cancer 95:1648-1652, 2006
67. Duk-Joo Lee, Ho-Suk Oh, Jung-Hye Choi, Young-Yeul Lee, In-Soon Kim, Myung-Ju Ahn. Phase II study of oxaliplatin, 5-fluorouracil, and leucovorin in relapsed or metastatic colorectal cancer as second line therapy. Cancer. Cancer Res Treat.2006 38(4), 201-205.
68. Sarah Park, Myung-Ju Ahn, Jin Seok Ahn, Jeeyun Lee, Yong Sang Hong, Byeong-Bae Park, Sang Chul Lee, In Gyun Hwang, Joon Oh Park, Hoyeong Lim, Won Ki Kang, Keunchil Park. Combination chemotherapy with paclitaxel and ifofamide as the third-line rgimen in patients with heavily pretreated small cell lung cancer. Lung Cancer 58:116-122, 2007
69. H-S Lee, ST Kim, J Lee, YS Choi, J-H Han, Y-C Ahn, K-S Lee, JS Ahn, MJ Ahn, K Kim, YM Shim, J Kim, K Park. Single institutional experience of thymic epithelial tumours over 11 years: clinical features and outcome and implications for future management. British Journal of Cancer 97, 22 – 28, 2007
70. Doyeun Oh, Nam Keun Kim, Moon Ju Jang, Hugh Chul Kim, Jae Hoon Lee, Jung Ae Lee, Myung-Ju Ahn,, Chul Soo Kim, Heung Sik Kim, Seonyang Park, Hyun Sook Chi, Yoo Hong Min, HOGS Investigators. Association of the 5,10-Methylenetetrahydrofolate Reductase (MTHFR C677T and A1298C) Polymorphisms in Korean Patients with Adult Acute Lymphoblastic Leukemia. Anticancer Research 27: 3419-3424, 2007
71. Joon Oh Park, Sang-We Kim, Jin Seok Ahn, Cheolwon Suh, Jung Shin Lee, Joung Soon Jang, Eun Kyung Cho, Sung Hyun Yang, Jin-Hyuk Choi, Dae Seog Heo, Suk Young Park, Sang Won Shin, Myung Ju Ahn, Jong Seok Lee, Young Ho Yun, Jae-Won Lee, Keunchil Park. Phase III Trial of Two Versus Four Additional Cycles in Patients Who Are Nonprogressive After Two Cycles of Platinum-Based Chemotherapy in Non–Small-Cell Lung Cancer. Journal of Clinical Oncology, Vol 25, No 33 (November 20), 2007: pp. 5233-5239
72. Jeeyun Lee, Tae-You Kim, Myung Ah Lee, Myung-Ju Ahn, Hoon-Kyo Kim, Ho-Young Lim, Nam Su Lee, Byung Joo Park, Jun Suk Kim, (Korean Cancer Study Group). Phase II trial of gemcitabine combined with cisplatin in patients with inoperable biliary tract carcinoma. Cancer Chemother Pharmacol 2008 61:47-52.
73. Park BB, Im YH, Hwang IG, Lee SC, Ahn JS, Ahn MJ, Lim HY, Kang WK, Park K. Salvage chemotherapy with mitomycin C, ifosfamide, and cisplatin (MIC) for previously treated metastatic or recurrent esophageal squamous cell carcinoma. Invest New Drugs. 2008 Aug;26(4):387-92. Epub 2008 Mar 27.
74. Ahn MJ, Park BB, Ahn JS, Kim SW, Kim HT, Lee JS, Kang JH, Cho JY, Song HS, Park SH, Sohn CH, Shin SW, Choi JH, Ki CS, Park CK, Holmes AJ, Jänne PA, Park K. Are there any ethnic differences in molecular predictors of erlotinib efficacy in advanced non-small cell lung cancer? Clin Cancer Res. 2008 Jun 15;14(12):3860-6
75. Jun HJ, Ahn MJ, Kim HS, Yi SY, Han J, Lee SK, Ahn YC, Jeong HS, Son YI, Baek JH, Park K. ERCC1 expression as a predictive marker of squamous cell carcinoma of the head and neck treated with cisplatin-based concurrent chemoradiation. Br J Cancer. 2008 Jul 8;99(1):167-72.
76. Hwang IG, Ahn MJ, Park BB, Ahn YC, Han J, Lee S, Kim J, Shim YM, Ahn JS, Park K. ERCC1 expression as a prognostic marker in N2(+) nonsmall-cell lung cancer patients treated with platinum-based neoadjuvant concurrent chemoradiotherapy. Cancer. 2008 Sep 15;113(6):1379-86.
77. Hong JY, Choi MK, Uhm JE, Park MJ, Lee J, Park YH, Ahn JS, Park K, Han JH, Ahn MJ. The role of palliative chemotherapy for advanced pulmonary pleomorphic carcinoma. Med Oncol. 2009:26:287-291
78. Chang MH, Kim KH, Jun HJ, Kim HS, Yi SY, Uhm JE, Park MJ, Lim DH, Ji SH, Hwang IG, Lee J, Park YH, Ahn JS, Ahn MJ, Park K. Irinotecan and oxaliplatin combination as the first- line treatment for patients with advanced non-small cell lung cancer. Cancer Chemother Pharmacol. 2009 64:917-924
79. Kim HS, Yi SY, Jun HJ, Ahn JS, Ahn MJ, Lee J, Kim Y, Cui ZY, Hong HJ, Kim JM, Li S, Hwang IG, Park K. L1 cell adhesion molecule as a predictor for recurrence in pulmonary carcinoids and large-cell neuroendocrine tumors. APMIS. 2009 Feb;117(2):140-6.
80. Kim HS, Park K, Jun HJ, Yi SY, Lee J, Ahn JS, Park YH, Kim S, Lee S, Ahn MJ. Comparison of survival in advanced non-small cell lung cancer patients in the pre- and post-gefitinib eras. Oncology. 2009;76(4):239-46.
81. Lee HY, Ahn MJ, Park YH, Ahn JS, Kim BS, Kim HK, Kim HT, Ryoo HM, Bae SH, Lee SS, Choi K, Hong DS, Lee KH, Kwon JH, Choi IS, Kim BS, Lee NS, Gong SJ, Park K. Adenocarcinoma has an excellent outcome with pemetrexed treatment in Korean patients: A prospective, multicenter trial. Lung Cancer. 2009 Dec;66(3):338-43.
82. Kim Y, Kim HS, Cui ZY, Lee HS, Ahn JS, Park CK, Park K, Ahn MJ. Clinicopathological implications of EpCAM expression in adenocarcinoma of the lung. Anticancer Res. 2009 May;29(5):1817-22.
83. Park S, Holmes-Tisch AJ, Cho EY, Shim YM, Kim J, Kim HS, Lee J, Park YH, Ahn JS, Park K, Jänne PA, Ahn MJ. Discordance of molecular biomarkers associated with epidermal growth factor receptor pathway between primary tumors and lymph node metastasis in non-small cell lung cancer. J Thorac Oncol. 2009 Jul;4(7):809-15.
84. Kim KH, Lee J, Lee JI, Nam DH, Kong DS, Ahn YC, Park HC, Jung Kwon O, Kim H, Chang MH, Yi SY, Ji SH, Park YH, Ahn JS, Park K, Ahn MJ. Can upfront systemic chemotherapy replace stereotactic radiosurgery or whole brain radiotherapy in the treatment of non-small cell lung cancer patients with asymptomatic brain metastases? Lung Cancer. 2010 68(2):258-63.
85. Uhm JE, Park BB, Ahn MJ, Lee J, Ahn JS, Kim SW, Kim HT, Lee JS,_Kang JH, Cho JY, Song HS, Park SH, Sohn CH, Shin SW, Choi JH, Park K. Erlotinib monotherapy for stage IIIB/IV non-small cell lung cancer. A multicenter trial by the Korean Cancer Study Group. J Thorac Oncol 2009; 4:1136-1143.
86. Chang MH, Lee J, Han J, Park YH, Ahn JS, Park K, Ahn MJ. Prognostic role of insulin-like growth factor-1 expression in small cell lung cancer. APMIS 2009;117;861-869.
87. Sun JM, Ahn MJ, Park MJ, Yi JH, Kim TS, Chung MJ, Park YH, Ahn JS, Park K. Accuracy of RECIST 1.1 for non-small cell lung cancer treated with EGFR tyrosine kiniase inhibitors. Lung Cancer 2010:69:105-109
88. Chung MK. Jeong H, Park SG, Ahn MJ, Baek C. Metabolic tumor volume of F18- fluorodeoxyglucose postiron emission tomography/computed tomography predicts short-term outcome to radiotherapy with or without chemotherapy in pharyngeal cancer. Clin Cancer Res 2009;15:5861-8.
89. Kim HS, Park YH, Lee J, Ahn JS, Park K, Han J, Ahn MJ. Clinical impact of phosphorylated signal transducer and activator of treanscription 3, epidermal growth factor receptor, p53 and vascular endothelial growth factor receptor 1 expression in resected adenocarcinoma of lung by using tissue microarray. Cancer 2010;116:676-85.
90. Lee DH, Park K, Kim JH, Lee J, Shin SW, Ahn MJ, Kim SW. Randomized phase III trial of gefitinib versus docetaxel in non-small cell lung cancer patients who have previously received platinum-based chemotherapy. Clin Cancer Res 2010;16:1307-14.
91. Lee DH, Kim SW, Suh C, Lee JS, Ahn JS, Ahn MJ, Park K, Yang SY. Multicenter phase II study of belotecan, a new camptothecin analog, and cisplatin for chemotherapy-naïve patients with extensive –disease small cell lung cancer. Cancer 2010;116:132-136.
92. Sun JM, Park JO, Won YW, Kim JH, Yun J, Lee J, Park YH, Ahn JS, Ahn MJ, Park K. Who are less likely to receive subsequent chemotherapy beyond first-line therapy for advanced non- small cell lung cancer? J J Thorac Oncol 2010; 5:540-545.
93. Kim ST, Lee J, Kim JH, Won YW, Sun JM, Yun J, Park YH, Ahn JS, Park K, Ahn MJ. Comparison of gefitnib versus erlotinib in patients with non-small cell lung cancer who failed previous chemotherapy. Cancer 2010:116;3025-3033.
94. Ho Yun Lee, Seung Hyup Hyun, Kyung Soo Lee, Byung-Tae Kim, Jhingook Kim, Young Mog Shim, Myung-Ju Ahn, Tae Sung Kim, Chin A Yi, Myung Jin Chung. Volume-Based Parameter of 18F-FDG PET/CT in Malignant Pleural Mesothelioma: Prediction of Therapeutic Response and Prognostic Implications. Ann Surg Oncol 17:2787-2794, 2010
95. Myung-Ju Ahn, Jeeyun Lee, Yun-Hee Park, Jin-Seok Ahn, Argyrios Ziogas, Jason A. Zell, Keunchil Park, Sai-Hong Ignatius Ou, Korean Ethnicity as Compared with White Ethnicity Is an Independent Favorable Prognostic Factor for Overall Survival in Non-small Cell Lung Cancer before and after the Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Era. J Thora Oncol 8:1185-1196, 2010
96. Jong-Mu Sun, Tae Sung Kim, Jeeyun Lee, Yeon Hee Park, Jin Seok Ahn, Hojoong Kim, O. Jung Kwon, Kyung Soo Lee, Keunchil Park, Myung-Ju Ahn. Unsuspected pulmonary emboli in lung cancer patients: The impact on survival and the significance of anticoagulation therapy Lung Cancer 69 :330–336, 2010
97. Chang MH, Ahn JS, Lee J, Kim KH, Park YH, Han J, Ahn MJ, Park K. The efficacy of pemetrexed as a third- or fourth-line therapy and the significance of thymidylate synthase expression in patients with advanced non-small cell lung cancer. Lung Cancer. 2010 Sep;69(3):323-9.
98. Min JH, Lee HY, Lee KS, Han J, Park K, Ahn MJ, Lee SJ. Stepwise evolution from a focal pure pulmonary ground-glass opacity nodule into an invasive lung adenocarcinoma: an observation for more than 10 years. Lung Cancer. 2010 Jul;69(1):123-6
99. Oh YH, Kim Y, Kim YP, Seo SW, Mitsudomi T, Ahn MJ, Park K, Kim HS. Rapid detection of the epidermal growth factor receptor mutation in non-small-cell lung cancer for analysis of acquired resistance using molecular beacons. J Mol Diagn. 2010 Sep;12(5):644-52.
100. Lee HY, Lee KS, Hwang HS, Lee JW, Ahn MJ, Park K, Kim TS, Yi CA, Chung MJ. Molecularly targeted therapy using bevacizumab for non-small cell lung cancer: a pilot study for the new CT response criteria. Korean J Radiol. 2010 Nov-Dec;11(6):618-26.
101. Kim ST, Lee J, Sun JM, Park YH, Ahn JS, Park K, Ahn MJ. Prognostic Model to Predict Outcomes in Non-Small Cell Lung Cancer Patients with Erlotinib as Salvage Treatment. Oncology. 2010 Nov 12;79(1-2):78-84.
102. Sun JM, Won YW, Kim ST, Kim JH, Choi YL, Lee J, Park YH, Ahn JS, Park K, Ahn MJ. The different efficacy of gefitinib or erlotinib according to epidermal growth factor receptor exon 19 and exon 21 mutations in Korean non-small cell lung cancer patients. J Cancer Res Clin Oncol. 2011 137:687-694
103. Sun JM, Ahn JS, Lee S, Kim JA, Lee J, Park YH, Park HC, Ahn MJ, Ahn YC, Park K. Predictors of skeletal-related events in non-small cell lung cancer patients with bone metastases. Lung Cancer. 2011 Jan;71(1):89-93.
104. Won YW, Park YH, Ahn MJ, Do IG, Ko YH, Park K. A phase II study of combination chemotherapy with capecitabine and cisplatin in patients with metastatic or recurrent squamous cell carcinoma of the head and neck. Ann Oncol. 2011 22:417-423.
105. Chang MH, Ahn HK, Lee J, Jung CK, Choi YL, Park YH, Ahn JS, Park K, Ahn MJ. Clinical impact of amphiregulin expression in patients with epidermal growth factor receptor (EGFR) wild-type nonsmall cell lung cancer treated with EGFR-tyrosine kinase inhibitors. Cancer. 2011 Jan 1;117(1):143-51.
106. Lee HY, Lee KS, Ahn MJ, Hwang HS, Lee JW, Park K, Ahn JS, Kim TS, Yi CA, Chung MJ. New CT response criteria in non-small cell lung cancer: Proposal and application in EGFR tyrosine kinase inhibitor therapy. Lung Cancer. 2011 73: 63-69
107. Seung-Tae Lee, Ji-Youn Kim, Min-Jung Kown, Sun Wook Kim, Jae Hoon Chung, Myung-Ju Ahn,Young Lyun Oh, Jong-Won Kim, and Chang-Seok Ki. Mutant Enrichment with 3=- Modified Oligonucleotides A Practical PCR Method for Detecting Trace Mutant DNAs The Journal of Molecular Diagnostics, Vol. 13, No. 6, November 2011, 657-668.
108. Sun JM, Nam MH, Chung JY, Im B, Lee SY, Suh YL, Ahn JS, Park K, Ahn MJ. Safety and pharmacokinetics of intrathecal administration of pemetrexed in rats. Cancer Chemother Pharmacol. 2011 68:531-538
109. Seung Tae Kim, Ji Eun Uhma, Jeeyun Lee, Jong-mu Sun, Insuk Sohn, Seon Woo Kim, Sin-Ho Jung, Yeon Hee Park, Jin Seok Ahn, Keunchil Park, Myung-Ju Ahn. Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy. Lung Cancer 2012; 75 (2012) 82– 88
110. Soohyeon Lee, Youngwook Kim, Jong-Mu Sun, Yoon La Choi,Jhin Gook Kim, Young-Mog Shim, Yeon Hee Park, Jin Seok Ahn, Keunchil Park, Jung Ho Han, Myung-Ju Ahn. Molecular profiles of EGFR, K-ras, c-met, and FGFR in pulmonary pleomorphic carcinoma, a rare lung malignancy. J Cancer Res Clin Oncol 2011 137:1203-1211.
111. Myung-Ju AHN, Chun-Ming TSAI, Te-Chun HSIA, Elaine WRIGHT, John Wen-Cheng CHANG, Heung Tae KIM, Joo-Hang KIM, Jin Hyoung KANG, Sang-We KIM, Eun-Jin BAE, Mijeong KANG, Johanna LISTER and Stefan WALZER. Cost-effectiveness of bevacizumab- based therapy versus cisplatin plus pemetrexed for the first-line treatment of advanced non- squamous NSCLC in Korea and Taiwan. Asia–Pacific Journal of Clinical Oncology 2011; 7(Suppl. 2): 22–33.
112. Gee-Chen CHANG, Myung-Ju AHN, Elaine WRIGHT, Heung Tae KIM, Joo-Hang KIM, Jin Hyoung KANG, Sang-We KIM, Steven SHERMAN and Stefan WALZER. Comparative effectiveness of bevacizumab plus cisplatin-based chemotherapy versus pemetrexed plus cisplatin treatment in East Asian non-squamous non-smal cell lung cancer patients applying real- life outcomes. Asia–Pacific Journal of Clinical Oncology 2011; 7(Suppl. 2): 34–40.
113. John Wen-Cheng CHANG, Sumitra THONGPRASERT, Elaine WRIGHT, Kenneth TSANG, Heung Tae KIM, Myung-Ju AHN, Joo-Hang KIM, Jin Hyoung KANG, Sang-We KIM and Stefan WALZER. An indirect comparison of bevacizumab plus cisplatin-gemcitabine and cisplatin plus pemetrexed treatment for patients with advanced first-line non-squamous non-small cell lung cancer in East Asia. Asia–Pacific Journal of Clinical Oncology 2011; 7(Suppl. 2): 13– 21.
114. Yi Kyung Kim , Ho Yun Lee, Kyung Soo Lee, Joungho Han, Myung-Ju Ahn, Keunchil Park, Young Mog Shim, Jhingook Kim. Dry Pleural Dissemination in Non–Small Cell Lung Cancer: Prognostic and Diagnostic Implications. Radiology: Volume 260: Number 2—August 2011.
115. Jong-Mu Sun a,e, Hyun Jung Jun a,e, Young Hyeh Ko b, Yeon Hee Park a, Yong Chan Ahn c, Young-Ik Son d, Jeong-Hwan Baek d, Keunchil Park a, Myung-Ju Ahn. Insulin-like growth factor binding protein-3, in association with IGF-1 receptor, can predict prognosis in squamous cell carcinoma of the head and neck. Oral Oncology 47 (2011) 714–719.
116. Jong-Mu Sun, Joungho Han, Jin Seok Ahn, Keunchil Park, Myung-Ju Ahn, Significance of Thymidylate Synthase and Thyroid Transcription Factor 1 Expression in Patients with Nonsquamous Non-small Cell Lung Cancer Treated with Pemetrexed-Based Chemotherapy. J Thorac Oncol. 2011;6: 1392–1399.
117. JONG-MU SUN, MYUNG-JU AHN, MIN JAE PARK, HUI-YOUNG LEE, JIN SEOK AHN, SEUNGKOO LEE, GU KANG, JOUNGHO HAN, YOUNG-IK SON, CHUNG-HWAN BAEK, YONG CHAN AHN, AND KEUNCHIL PARK. EXPRESSION OF EXCISION REPAIR CROSS-COMPLEMENTATION GROUP 1 AS PREDICTIVE MARKER FOR NASOPHARYNGEAL CANCER TREATED WITH CONCURRENT CHEMORADIOTHERAPY. Int. J. Radiation Oncology Biol. Phys., Vol. 80, No. 3, pp. 655–660, 2011
118. Seung Tae Kim, Ji Eun Uhma, Jeeyun Lee, Jong-mu Sun, Insuk Sohn, Seon Woo Kim, Sin-Ho Jung, Yeon Hee Park, Jin Seok Ahn, Keunchil Park, Myung-Ju Ahn. Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy. Lung Cancer 2012 :75:82-88.
119. Myung-Ju Ahn, Hong-Hee Won, Jeeyun Lee, Seung-Tae Lee, Jong-Mu Sun, Yeon Hee Park, Jin Seok Ahn, O Jung Kwon, Hojoong Kim, Young Mog Shim, Jhingook Kim, Kwhanmien Kim,Yeul Hong Kim, Jae Yong Park, Jong-Won Kim, Keunchil Park. The 18p11.22 locus is associated with never smoker non-small cell lung cancer susceptibility in Korean populations. Hum Genet 2012:131:365-372
120. Youngwook Kim, Jeonghun Ko, ZhengYun Cui, Amir Abolhoda, Jin Seok Ahn, Sai-Hong Ou, Myung-Ju Ahn, and Keunchil Park The EGFR T790M Mutation in Acquired Resistance to an Irreversible Second-Generation EGFR Inhibitor. Molecular Cancer Thera 11(3);784-91, 2012
121. Myung-Ju Ahn, Shin-Young Park, Won Kyu Kim, Ju Hwan Cho, Brian Junho Chang, Dong Jo Kim, Jin Seok Ahn, Keunchil Park, Joong-Soo Han. A single nucleotide polymorphism in the phospholipase D1 gene is associated with risk of non-small cell lung cancer. Int J Biomed Sci 2012:8(2) 121-128
122. Sung JY, Ahn HK, Kwon JE, Jeong H, Baek CH, Son YI, Ahn YC, Park K, Ahn MJ, Ko YH. Reappraisal of KIT mutation in adenoid cystic carcinomas of the salivary gland. J Oral Pathol Med. 2012 May;41(5):415-23.
123. Park S, Choi YL, Sung CO, An J, Seo J, Ahn MJ, Ahn JS, Park K, Shin YK, Erkin OC, Song K, Kim J, Shim YM, Han J. High MET copy number and MET overexpression: poor outcome in non-small cell lung cancer patients. Histol Histopathol. 2012 Feb;27(2):197-207
124. Lee HY, Lee KS, Park J, Han J, Kim BT, Kwon OJ, Ahn YC, Ahn MJ, Park K, Kim J, Shim YM. Baseline SUVmax at PET-CT in stage IIIA non-small-cell lung cancer patients undergoing surgery after neoadjuvant therapy: prognostic implication focused on histopathologic subtypes. Acad Radiol. 2012 Apr;19(4):440-5.
125. Han JY, Park K, Kim SW, Lee DH, Kim HY, Kim HT, Ahn MJ, Yun T, Ahn JS, Suh C, Lee JS, Yoon SJ, Han JH, Lee JW, Jo SJ, Lee JS. First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung. J Clin Oncol. 2012 Apr 1;30(10):1122-8.
126. Ahn HK, Han B, Lee SJ, Lim T, Sun JM, Ahn JS, Ahn MJ, Park K. ALK inhibitor crizotinib combined with intrathecal methotrexate treatment for non-small cell lung cancer with leptomeningeal carcinomatosis. Lung Cancer. 2012 May;76(2):253-4.
127. Ahn MJ, Yang JC, Liang J, Kang JH, Xiu Q, Chen YM, Blair JM, Peng G, Linn C, Orlando M. Randomized phase II trial of first-line treatment with pemetrexed-cisplatin, followed sequentially by gefitinib or pemetrexed, in East Asian, never-smoker patients with advanced non-small cell lung cancer. Lung Cancer. 2012 Aug;77(2):346-52.
128. Sun JM, Ahn MJ, Ahn JS, Um SW, Kim H, Kim HK, Choi YS, Han J, Kim J, Kwon OJ, Shim YM, Park K. Chemotherapy for pulmonary large cell neuroendocrine carcinoma: similar to that for small cell lung cancer or non-small cell lung cancer? Lung Cancer. 2012 Aug;77(2):365-70.
129. Sun JM, Lee KH, Kim SW, Lee DH, Min YJ, Yun HJ, Kim HK, Song HS, Kim YH, Kim BS, Hwang IG, Lee K, Jo SJ, Lee JW, Ahn JS, Park K, Ahn MJ; Korean Cancer Study Group. Gefitinib versus pemetrexed as second-line treatment in patients with nonsmall cell lung cancer previously treated with platinum-based chemotherapy (KCSG-LU08-01): an open-label, phase 3 trial. Cancer. 2012 Dec 15;118(24):6234-42.
130. Ahn MJ, Sun JM, Ahn JS, Park K. The effectiveness of maintenance pharmacotherapies for non- small cell lung cancer. Clin Med Insights Oncol. 2012;6:253-62
131. Cho SH, Park LC, Ji JH, Park S, Hwang DW, Lee JY, Choi YL, Han JH, Sun JM, Ahn JS, Park K, Ahn MJ. Efficacy of EGFR tyrosine kinase inhibitors for non-adenocarcinoma NSCLC patients with EGFR mutation. Cancer Chemother Pharmacol. 2012 Aug;70(2):315-20.
132. Ji JH; Korean Cancer Study Group (KCSG), Yun T, Kim SB, Kang JH, Park JC, Cho IS, Sohn CH, Heo DS, Jang JS, Shin SW, Hwang DW, Sun JM, Park K, Ahn MJ. A prospective multicentre phase II study of cisplatin and weekly docetaxel as first-line treatment for recurrent or metastatic nasopharyngeal cancer (KCSG HN07-01). Eur J Cancer. 2012 Nov;48(17):3198- 204.
133. Yoon HJ, Lee HY, Lee KS, Choi YL, Ahn MJ, Park K, Ahn JS, Sun JM, Kim J, Kim TS, Chung MJ, Yi CA. Repeat biopsy for mutational analysis of non-small cell lung cancers resistant to previous chemotherapy: adequacy and complications. Radiology. 2012 Dec;265(3):939-48.
134. Bae SH, Ahn YC, Nam H, Park HC, Pyo HR, Shim YM, Kim J, Kim K, Ahn JS, Ahn MJ, Park K. High dose involved field radiation therapy as salvage for loco-regional recurrence of non- small cell lung cancer. Yonsei Med J. 2012 Nov 1;53(6):1120-7
135. Lee HY, Ahn HK, Jeong JY, Kwon MJ, Han JH, Sun JM, Ahn JS, Park K, Choi YL, Ahn MJ. Favorable clinical outcomes of pemetrexed treatment in anaplastic lymphoma kinase positive non-small-cell lung cancer. Lung Cancer. 2013 Jan;79(1):40-5.
136. Kim YN, Lee HY, Lee KS, Seo JB, Chung MJ, Ahn MJ, Park K, Kim TS, Yi CA. Dual-energy CT in patients treated with anti-angiogenic agents for non-small cell lung cancer: new method of monitoring tumor response? Korean J Radiol. 2012 Nov;13(6):702-10.
137. Sun JM, Choi YL, Won JK, Hirsch FR, Ahn JS, Ahn MJ, Park K. A dramatic response to crizotinib in a non-small-cell lung cancer patient with IHC-positive and FISH-negative ALK. J Thorac Oncol. 2012 Dec;7(12):e36-8.
138. Lira ME, Kim TM, Huang D, Deng S, Koh Y, Jang B, Go H, Lee SH, Chung DH, Kim WH, Schoenmakers EF, Choi YL, Park K, Ahn JS, Sun JM, Ahn MJ, Kim DW, Mao M. Multiplexed gene expression and fusion transcript analysis to detect ALK fusions in lung cancer. J Mol Diagn. 2013 Jan;15(1):51-61.
139. Ahn HK, Choi YL, Han JH, Ahn YC, Kim K, Kim J, Shim YM, Um SW, Kim H, Kwon OJ, Sun JM, Ahn JS, Park K, Ahn MJ. Epidermal growth factor receptor mutation and treatment outcome of mediastinoscopic N2 positive non-small cell lung cancer patients treated with neoadjuvant chemoradiotherapy followed by surgery. Lung Cancer. 2013 Mar;79(3):300-6.
140. Park SY, Lim SY, Um SW, Koh WJ, Chung MP, Kim H, Kwon OJ, Park HK, Kim SJ, Im YH, Ahn MJ, Suh GY. Outcome and predictors of mortality in patients requiring invasive mechanical ventilation due to acute respiratory failure while undergoing ambulatory chemotherapy for solid cancers. Support Care Cancer. 2013 Jan 12. [Epub ahead of print]
141. Lee SJ, Lee JI, Nam DH, Ahn YC, Han JH, Sun JM, Ahn JS, Park K, Ahn MJ. Leptomeningeal carcinomatosis in non-small-cell lung cancer patients: impact on survival and correlated prognostic factors. J Thorac Oncol. 2013 Feb;8(2):185-91.
142. Ahn HK, Jeon K, Yoo H, Han B, Lee SJ, Park H, Lee MJ, Ha SY, Han JH, Sun JM, Ahn JS, Ahn MJ, Park K. Successful Treatment with Crizotinib in Mechanically Ventilated Patients with ALK Positive Non-Small-Cell Lung Cancer. J Thorac Oncol. 2013 Feb;8(2):250-3.
143. Hirsch FR, Jänne PA, Eberhardt WE, Cappuzzo F, Thatcher N, Pirker R, Choy H, Kim ES, Paz- Ares L, Gandara DR, Wu YL, Ahn MJ, Mitsudomi T, Shepherd FA, Mok TS. Epidermal Growth Factor Receptor Inhibition in Lung Cancer: Status 2012. J Thorac Oncol. 2013 Mar8(3) 373-384.
144. Han B, Sun JM, Ahn JS, Park K, Ahn MJ. Clinical outcomes of atypical carcinoid tumors of the lung and thymus: 7-year experience of a rare malignancy at single institute. Med Oncol. 2013 Mar;30(1):479.
145. Park S, Kim IR, Baek KK, Lee SJ, Chang WJ, Maeng CH, Hong JY, Choi MK, Kim YS, Sun JM, Ahn JS, Park K, Jo J, Jung SH, Ahn MJ. Prospective analysis of quality of life in elderly patients treated with adjuvant chemotherapy for non-small-cell lung cancer. Ann Oncol. 2013 Jun 24(6);1630-9.
146. Huang D, Kim DW, Kotsakis A, Deng S, Lira P, Ho SN, Lee NV, Vizcarra P, Cao JQ, Christensen JG, Kim TM, Sun JM, Ahn JS, Ahn MJ, Park K, Mao M. Multiplexed deep sequencing analysis of ALK kinase domain identifies resistance mutations in relapsed patients following crizotinib treatment. Genomics. 2013 Feb 20. [Epub ahead of print]
147. Jhun BW, Lee KJ, Jeon K, Suh GY, Chung MP, Kim H, Kwon OJ, Sun JM, Ahn JS, Ahn MJ, Park K, Choi JY, Lee KS, Han J, Um SW. Clinical applicability of staging small cell lung cancer according to the seventh edition of the TNM staging system. Lung Cancer. 2013 Jul;81(1):65-70.
148. Sun JM, Ahn YC, Choi EK, Ahn MJ, Ahn JS, Lee SH, Lee DH, Pyo H, Song SY, Jung SH, Jo JS, Jo J, Sohn HJ, Suh C, Lee JS, Kim SW, Park K. Phase III trial of concurrent thoracic radiotherapy with either first- or third-cycle chemotherapy for limited-disease small-cell lung cancer. Ann Oncol. 2013 Apr 16. [Epub ahead of print]
149. Moon SH, Cho SH, Park LC, Ji JH, Sun JM, Ahn JS, Park K, Choi JY, Ahn MJ. Metabolic response evaluated by (18)F-FDG PET/CT as a potential screening tool in identifying a subgroup of patients with advanced non-small cell lung cancer for immediate maintenance therapy after first-line chemotherapy. Eur J Nucl Med Mol Imaging. 2013 Jul;40(7):1005-13.
150. Ahn MJ, Park SY, Kim WK, Cho JH, Chang BJ, Kim DJ, Ahn JS, Park K, Han JS. A Single Nucleotide Polymorphism in the Phospholipase D1 Gene is Associated with Risk of Non-Small Cell Lung Cancer. Int J Biomed Sci. 2012 Jun;8(2):121-8.
151. Kim YS, Sun JM, Ahn JS, Ahn MJ, Park K. The optimal duration of vitamin supplementation prior to the first dose of pemetrexed in patients with non-small-cell lung cancer. Lung Cancer. 2013 Aug;81(2):231-5.
152. Park S, Ahn MJ, Ahn JS, Sun JM, Shim YM, Kim J, Choi YS, Kim K, Shin S, Ahn Y, Kwon OJ, Kim H, Lee SJ, Chang WJ, Park K. A Prospective Phase II Trial of Induction Chemotherapy with Docetaxel/Cisplatin for Masaoka Stage III/IV thymic Epithelial Tumors. J Thorac Oncol. 2013 Jul;8(7):959-66.
153. Lim SH, Lee JY, Sun JM, Kim KM, Ahn JS, Ahn MJ, Park K. A new KIT gene mutation in thymic cancer and a promising response to imatinib. J Thorac Oncol. 2013 Oct;8(10):e91-2.
154. Kim HK, Lee HY, Choi YL, Choi SJ, Choi H, Lee J, Han J, Ahn MJ, Lee KS, Kim J. Assessment of intratumoral heterogeneity of oncogenic driver mutations in surgically-resected lung adenocarcinoma: implications of percutaneous biopsy-based molecular assay for target- directed therapy. Anticancer Res. 2014 Feb;34(2):707-14.
155. Lee JY, Lim SH, Lee JY, Kim JH, Choi KH, Park K, Sun JM, Ahn JS, Ahn MJ. Tumor lysis syndrome in a solid tumor: a case report of a patient with invasive thymoma. Cancer Res Treat. 2013 Dec;45(4):343-8.
156. Sun JM, Hwang DW, Ahn JS, Ahn MJ, Park K. Prognostic and Predictive Value of KRAS Mutations in Advanced Non-Small Cell Lung Cancer. PLoS One. 2013 May 28;8(5):e64816.
157. Shaw AT, Kim DW, Nakagawa K, Seto T, Crinó L, Ahn MJ, De Pas T, Besse B, Solomon BJ, Blackhall F, Wu YL, Thomas M, O'Byrne KJ, Moro-Sibilot D, Camidge DR, Mok T, Hirsh V, Riely GJ, Iyer S, Tassell V, Polli A, Wilner KD, Jänne PA. Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer. N Engl J Med. 2013 Jun 20;368(25):2385-94
158. Maeng CH, Lee HY, Kim YW, Choi MK, Hong JY, Jung HA, Lee KS, Kim H, Kwon OJ, Sun JM, Ahn JS, Park K, Um SW, Ahn MJ. High-throughput molecular genotyping for small biopsy samples in advanced non-small cell lung cancer patients. Anticancer Res. 2013 Nov;33(11):5127-33.
159. Rittmeyer A, Gorbunova V, Vikström A, Scherpereel A, Kim JH, Ahn MJ, Chella A, Chouaid C, Campbell AK, Barlesi F. Health-related quality of life in patients with advanced nonsquamous non-small-cell lung cancer receiving bevacizumab or bevacizumab-plus-pemetrexed maintenance therapy in AVAPERL (MO22089). J Thorac Oncol. 2013 Nov;8(11):1409-16.
160. Ahn JS, Lee KH, Sun JM, Park K, Kang ES, Cho EK, Lee DH, Kim SW, Lee GW, Kang JH, Lee JS, Lee JW, Ahn MJ. A randomized, phase II study of vandetanib maintenance for advanced or metastatic non-small-cell lung cancer following first-line platinum-doublet chemotherapy. Lung Cancer. 2013 Dec;82(3):455-60.
161. Sun JM, Ahn MJ, Choi YL, Ahn JS, Park K. Clinical implications of T790M mutation in patients with acquired resistance to EGFR tyrosine kinase inhibitors. Lung Cancer. 2013 Nov;82(2):294-8.
162. Sun JM, Kim JR, Do IG, Lee SY, Lee J, Choi YL, Ahn JS, Ahn MJ, Park K. A phase-1b study of everolimus plus paclitaxel in patients with small-cell lung cancer. Br J Cancer. 2013 Sep 17;109(6):1482-7
163. Barlesi F, Scherpereel A, Rittmeyer A, Pazzola A, Ferrer Tur N, Kim JH, Ahn MJ, Aerts JG, Gorbunova V, Vikström A, Wong EK, Perez-Moreno P, Mitchell L, Groen HJ. Randomized phase III trial of maintenance bevacizumab with or without pemetrexed after first-line induction with bevacizumab, cisplatin, and pemetrexed in advanced nonsquamous non-small-cell lung cancer: AVAPERL (MO22089). J Clin Oncol. 2013 Aug 20;31(24):3004-11.
164. Kim Y, Hammerman PS, Kim J, Yoon JA, Lee Y, Sun JM, Wilkerson MD, Pedamallu CS, Cibulskis K, Yoo YK, Lawrence MS, Stojanov P, Carter SL, McKenna A, Stewart C, Sivachenko AY, Oh IJ, Kim HK, Choi YS, Kim K, Shim YM, Kim KS, Song SY, Na KJ, Choi YL, Hayes DN, Kim J, Cho S, Kim YC, Ahn JS, Ahn MJ, Getz G, Meyerson M, Park K. Integrative and comparative genomic analysis of lung squamous cell carcinomas in East asian patients. J Clin Oncol. 2014 Jan 10;32(2):121-8.
165. Hyun SH, Ahn HK, Kim H, Ahn MJ, Park K, Ahn YC, Kim J, Shim YM, Choi JY. Volume- based assessment by (18)F-FDG PET/CT predicts survival in patients with stage III non-small- cell lung cancer. Eur J Nucl Med Mol Imaging. 2014 Jan;41(1):50-8.
166. Sun JM, Lira M, Pandya K, Choi YL, Ahn JS, Mao M, Han J, Park K, Ahn MJ, Kim J. Clinical characteristics associated with ALK rearrangements in never-smokers with pulmonary adenocarcinoma. Lung Cancer. 2014 Feb;83(2):259-64.
167. Hyun SH, Ahn HK, Kim H, Ahn MJ, Park K, Ahn YC, Kim J, Shim YM, Choi JY. Volume- based assessment by (18)F-FDG PET/CT predicts survival in patients with stage III non-small- cell lung cancer. Eur J Nucl Med Mol Imaging. 2014 Jan;41(1):50-8.
168. Lira ME, Choi YL, Lim SM, Deng S, Huang D, Ozeck M, Han J, Jeong JY, Shim HS, Cho BC, Kim J, Ahn MJ, Mao M. A Single-Tube Multiplexed Assay for Detecting ALK, ROS1, and RET Fusions in Lung Cancer. J Mol Diagn. 2014 Mar 16(2):229-243.
169. Chang WJ, Sun JM, Lee JY, Ahn JS, Ahn MJ, Park K. A retrospective comparison of adjuvant chemotherapeutic regimens for non-small cell lung cancer (NSCLC): paclitaxel plus carboplatin versus vinorelbine plus cisplatin. Lung Cancer. 2014 Apr;84(1):51-5.
170. Lee H, Ahn YC, Pyo H, Kim B, Oh D, Nam H, Lee E, Sun JM, Ahn JS, Ahn MJ, Park K, Choi YS, Kim J, Zo JI, Shim YM. Pretreatment clinical mediastinal nodal bulk and extent do not influence survival in N2-positive stage IIIA non-small cell lung cancer patients treated with trimodality therapy. Ann Surg Oncol. 2014 Jun;21(6):2083-90.
171. Barlesi F, Scherpereel A, Gorbunova V, Gervais R, Vikström A, Chouaid C, Chella A, Kim JH, Ahn MJ, Reck M, Pazzola A, Kim HT, Aerts JG, Morando C, Loundou A, Groen HJ, Rittmeyer A. Maintenance bevacizumab-pemetrexed after first-line cisplatin-pemetrexed-bevacizumab for advanced nonsquamous nonsmall-cell lung cancer: updated survival analysis of the AVAPERL (MO22089) randomized phase III trial. Ann Oncol. 2014 May;25(5):1044-52.
172. Chong Y, Kim JH, Lee HY, Ahn YC, Lee KS, Ahn MJ, Kim J, Shim YM, Han J, Choi YL. Quantitative CT variables enabling response prediction in neoadjuvant therapy with EGFR-TKIs: are they different from those in neoadjuvant concurrent chemoradiotherapy? PLoS One. 2014 Feb 26;9(2):e88598.
173. Lee JY, Lim SH, Kim M, Kim S, Jung HA, Chang WJ, Choi MK, Hong JY, Lee SJ, Sun JM, Ahn JS, Park K, Ahn MJ. Is there any predictor for clinical outcome in EGFR mutant NSCLC patients treated with EGFR TKIs? Cancer Chemother Pharmacol. 2014 May;73(5):1063-70.
174. Choi MK, Hong JY, Chang W, Kim M, Kim S, Jung HA, Lee SJ, Park S, Chung MP, Sun JM, Park K, Ahn MJ, Ahn JS. Safety and efficacy of gemcitabine or pemetrexed in combination with a platinum in patients with non-small-cell lung cancer and prior interstitial lung disease. Cancer Chemother Pharmacol. 2014 Jun;73(6):1217-25.
175. Lim SH, Lee JY, Sun JM, Ahn JS, Park K, Ahn MJ. Comparison of clinical outcomes following gefitinib and erlotinib treatment in non-small-cell lung cancer patients harboring an epidermal growth factor receptor mutation in either exon 19 or 21. J Thorac Oncol. 2014 Apr;9(4):506-11.
176. Ou SH, Soo RA, Kubo A, Kawaguchi T, Ahn MJ. Will the Requirement by the US FDA to Simultaneously Co-Develop Companion Diagnostics (CDx) Delay the Approval of Receptor Tyrosine Kinase Inhibitors for RTK-Rearranged (ROS1-, RET-, AXL-, PDGFR-α-, NTRK1-) Non-Small Cell Lung Cancer Globally? Front Oncol. 2014 Apr 1;4:58.
177. Ahn MJ, Kim SW, Cho BC, Ahn JS, Lee DH, Sun JM, Massey D, Kim M, Shi Y, Park K. Phase II study of Afatinib as third-line treatment for patients in Korea with stage IIIB/IV non- small cell lung cancer harboring wild-type EGFR. Oncologist. 2014 Jul;19(7):702-3.
178. Ahn S, Choi IH, Han J, Kim J, Ahn MJ. Pleural mesothelioma: an institutional experience of 66 cases. Korean J Pathol. 2014 Apr;48(2):91-9.
179. Yang JC, Kang JH, Mok T, Ahn MJ, Srimuninnimit V, Lin CC, Kim DW, Tsai CM, Barraclough H, Altug S, Orlando M, Park K. First-line pemetrexed plus cisplatin followed by gefitinib maintenance therapy versus gefitinib monotherapy in East Asian patients with locally advanced or metastatic non-squamous non-small cell lung cancer: a randomised, phase 3 trial. Eur J Cancer. 2014 Sep;50(13):2219-30.
180. Kim SM, Kim MJ, Jung HA, Sun JM, Choi YL, Ko YH, Park K, Baek CH, Son YI, Ahn MJ. The presence of ALK Translocation in Sarcomatoid Carcinoma of Head and Neck and Treatment effect of crizotinib: A Case series. Head Neck. 2014 Oct 1. doi: 10.1002/hed.23884. [Epub ahead of print]
181. Ku BM, Jho EH, Bae YH, Sun JM, Ahn JS, Park K, Ahn MJ. BYL719, a selective inhibitor of phosphoinositide 3-Kinase α, enhances the effect of selumetinib (AZD6244, ARRY-142886) in KRAS-mutant non-small cell lung cancer. Invest New Drugs. 2014 Oct 25. [Epub ahead of print]
182. Ku B, Jung H, Sun JM, Ko Y, Jeong HS, Son YI, Baek CH, Park K, Ahn MJ. High-throughput profiling identifies clinically actionable mutations in salivary duct carcinoma. J Transl Med. 2014 Oct 25;12(1):299. [Epub ahead of print]
183. Sun JM, Choi YL, Ji JH, Ahn JS, Kim KM, Han J, Ahn MJ, Park K. Small cell lung cancer detection in never-smokers: clinical characteristics and multigene mutation profiling using targeted next-generation sequencing. Ann Oncol. 2014 Oct 29. pii: mdu504. [Epub ahead of print]
184. Yang JC, Ahn MJ, Nakagawa K, Tamura T, Barraclough H, Enatsu S, Cheng R, Orlando M. Pemetrexed Continuation Maintenance in Patients with Nonsquamous Non-small Cell Lung Cancer: Review of Two East Asian Trials in Reference to PARAMOUNT. Cancer Res Treat. 2014 Sep 15. doi: 10.4143/crt.2013.266. [Epub ahead of print]
185. Kim HS, Kwon HJ, Jung I, Yun MR, Ahn MJ, Kang BW, Sun JM, Kim SB, Yoon DH, Park KU, Lee SH, Koh YW, Kim SH, Choi EC, Koo DH, Sohn JH, Kim B, Kwon NJ, Yun HJ, Lee MG, Lee JH, Kim TM, Kim HR, Kim JH, Paik S, Cho BC. Phase II Clinical and Exploratory Biomarker Study of Dacomitinib in Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of Head and Neck. Clin Cancer Res. 2014 Nov 25. pii: clincanres.1756.2014. [Epub ahead of print]
186.
Research Interest Main interest is focused on the clinical trials and correlative translational research for the development of predictive and prognostic marker in lung cancer in terms of personalized therapy. Recently, research has been focused on the establishment of xenograft model from patient tumor for the development of drug discovery and reposition of targeted drugs and the development of non-small cell lung cancer genome atlas.
Myung-Ju Ahn, M.D.
17 Dec 2014